Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
26 avr. 2023 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
20 févr. 2023 07h00 HE
|
Oxford BioMedica plc
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford BiomedicaStuart...
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
22 nov. 2022 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
14 nov. 2022 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a...
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
07 oct. 2022 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
15 sept. 2022 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A GLOBAL VIRAL VECTOR LEADER Oxford, UK – 15 September 2022:...
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
26 juil. 2022 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or...
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
26 juil. 2022 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a...
Oxford Biomedica Preliminary Results
20 avr. 2022 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading...
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
11 mars 2022 07h00 HE
|
Oxford BioMedica plc
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc...